Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence.
Alexandra KilianMarianne S ClancyScott OlitskyJames R GossageMarie E FaughnanPublished in: Vascular medicine (London, England) (2020)